Chemomab Therapeutics Ltd. (CMMB)
2.59
-0.10
(-3.72%)
USD |
NASDAQ |
Sep 10, 16:00
2.59
0.00 (0.00%)
After-Hours: 20:00
Chemomab Therapeutics EPS Diluted (Quarterly) : -0.275 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.275 |
| March 31, 2026 | -0.2218 |
| December 31, 2025 | -0.2407 |
| September 30, 2025 | -0.2829 |
| June 30, 2025 | -0.3626 |
| March 31, 2025 | -0.5794 |
| December 31, 2024 | -0.6338 |
| September 30, 2024 | -0.1992 |
| June 30, 2024 | -0.2529 |
| March 31, 2024 | -0.2752 |
| December 31, 2023 | -0.2654 |
| September 30, 2023 | -0.3441 |
| June 30, 2023 | -0.7108 |
| March 31, 2023 | -0.7848 |
| December 31, 2022 | -0.7093 |
| September 30, 2022 | -0.6944 |
| June 30, 2022 | -0.5336 |
| March 31, 2022 | -0.441 |
| December 31, 2021 | -0.442 |
| September 30, 2021 | -0.2616 |
| June 30, 2021 | -0.2571 |
| March 31, 2021 | -0.2151 |
| December 31, 2020 | -1.165 |
| September 30, 2020 | -1.330 |
| June 30, 2020 | -1.894 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.909 |
| December 31, 2019 | 4.894 |
| September 30, 2019 | -15.56 |
| June 30, 2019 | -9.561 |
| March 31, 2019 | -30.23 |
| December 31, 2018 | -2.307 |
| September 30, 2018 | -3.379 |
| June 30, 2018 | -10.88 |
| March 31, 2018 | -7.386 |
| December 31, 2017 | -162.81 |
| September 30, 2017 | -161.55 |
| June 30, 2017 | -7.890 |
| March 31, 2017 | -5.981 |
| December 31, 2016 | -3.645 |
| September 30, 2016 | -5.817 |
| June 30, 2016 | -4.724 |
| March 31, 2016 | -3.100 |
| December 31, 2015 | -5.162 |
| September 30, 2015 | -3.098 |
| June 30, 2015 | -12.00 |
| March 31, 2015 | -15.14 |
| December 31, 2014 | -8.152 |
| September 30, 2014 | -13.27 |
| June 30, 2014 | -11.64 |
| March 31, 2014 | -13.99 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| BioLineRx Ltd. | -0.6957 |
| XTL Biopharmaceuticals Ltd. | -- |
| Kamada Ltd. | 0.1605 |
| Can-Fite BioPharma Ltd. | -- |
| Galmed Pharmaceuticals Ltd. | -2.860 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.202M |
| Total Expenses (Quarterly) | 2.202M |
| Enterprise Value | 12.80M |
| Earnings Yield | -39.40% |
| Normalized Earnings Yield | -39.42 |